# CGEM (Cullinan Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Cullinan Therapeutics, Inc. reported $322.6M in total assets and a net loss of $203.5M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/CGEM
- Markdown: https://convexityos.com/fundamentals/CGEM.md
- SEC CIK: 0001789972
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:33 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001789972&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$218.8M | Operating profit |
| Net Income | FY 2025 | -$203.5M | GAAP bottom line |
| Diluted EPS | FY 2025 | -- | Split-adjusted |
| Free Cash Flow | FY 2025 | -$175.8M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $289.6M | Total debt: $2.00M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | $0 | $18.94M | $0 |
| Research & Development | $187.4M | $142.9M | $148.2M | $91.95M | $57.75M | $43.21M |
| Total Operating Expenses | $241.6M | $196.9M | $190.6M | $132.1M | $86.90M | $60.34M |
| **Operating Income** | -$241.6M | -$196.9M | -$191.1M | $144.6M | -$67.95M | -$60.34M |
| **EBITDA** | -$241.3M | -$196.6M | -$190.8M | $144.7M | -$67.90M | -$60.27M |
| Interest Income | $22.21M | $29.66M | $21.63M | $6.61M | $477K | $888K |
| Income Before Tax | -$219.9M | -$167.5M | -$169.2M | $151.3M | -$67.48M | -- |
| Income Tax Expense | $0 | $117K | -$14.12M | $42.12M | $0 | -- |
| **Net Income** | -$219.9M | -$167.4M | -$153.2M | $111.2M | -$65.57M | -$51.80M |
| Basic EPS | -- | -- | -$3.69 | $2.46 | -$1.52 | -$2.60 |
| **Diluted EPS** | -- | -- | -$3.69 | $2.38 | -$1.52 | -$2.60 |
| Basic Shares Outstanding | -- | -- | 41.5M | 45.2M | 43.1M | 19.9M |
| Diluted Shares Outstanding | -- | -- | 41.5M | 46.6M | 43.1M | 19.9M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $40.17M | $44.44M | $42.12M | $42.95M | $41.97M | $61.03M | $41.46M | $40.49M |
| Total Operating Expenses | $52.60M | $57.25M | $53.70M | $55.26M | $55.59M | $75.80M | $55.00M | $55.05M |
| **Operating Income** | -$52.60M | -$57.25M | -$53.70M | -$55.26M | -$55.59M | -$75.80M | -$55.00M | -$55.05M |
| **EBITDA** | -$52.55M | -$57.17M | -$53.62M | -$55.18M | -$55.52M | -$75.72M | -$54.92M | -$54.97M |
| Interest Income | $3.29M | $3.65M | $4.10M | $4.62M | $5.09M | $5.92M | $6.58M | $7.51M |
| **Net Income** | -$49.39M | -$53.70M | -$49.66M | -$50.71M | -$50.61M | -$70.06M | -$48.50M | -$47.65M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $88.33M | $83.00M | $98.43M | $156.2M | $59.77M | $168.2M |
| Short-Term Investments | $289.6M | $316.0M | $368.6M | $311.1M | $230.7M | $42.01M |
| **Cash & Short-Term Investments** | $377.9M | $399.0M | $467.1M | $467.3M | $290.5M | $210.2M |
| Other Current Assets | -- | -- | $3.90M | -- | -- | -- |
| **Total Current Assets** | $386.8M | $414.7M | $480.2M | $474.5M | $296.6M | $212.3M |
| Property, Plant & Equipment, Net | $421K | $683K | $989K | $1.17M | $77K | $130K |
| Long-Term Investments | $58.27M | $204.4M | $0 | $80.88M | $140.4M | $0 |
| Other Non-Current Assets | $297K | $366K | $459K | $459K | $147K | $2.30M |
| **Total Non-Current Assets** | $61.62M | $207.2M | $3.99M | $86.64M | $140.6M | $2.43M |
| **Total Assets** | $448.4M | $621.8M | $484.2M | $561.1M | $437.2M | $214.7M |
| Accounts Payable | $841K | $1.68M | $2.49M | $2.66M | $3.17M | $9.68M |
| Other Current Liabilities | $996K | $1.44M | $914K | $1.96M | $973K | -- |
| **Total Current Liabilities** | $37.74M | $30.65M | $28.14M | $22.50M | $11.75M | $14.32M |
| **Total Non-Current Liabilities** | $1.90M | $849K | $2.15M | $3.59M | $65K | $74K |
| **Total Liabilities** | $39.64M | $31.50M | $30.29M | $26.09M | $11.81M | $14.39M |
| **Total Debt (incl. Leases)** | $2.68M | $2.15M | $3.59M | $5.01M | -- | -- |
| Common Stock | $6.0K | $6.0K | $4.0K | $5.0K | $4.0K | $3.0K |
| Retained Earnings | -$588.1M | -$368.2M | -$200.9M | -$47.70M | -$158.9M | -$93.34M |
| Accumulated Other Comp. Income | $1.02M | -$133K | -$129K | -$2.60M | -$838K | -$2.0K |
| **Total Stockholders' Equity** | $408.7M | $590.3M | $453.7M | $535.0M | $425.0M | $199.0M |
| Total Equity | $408.7M | $590.3M | $453.9M | $535.0M | $425.4M | $200.3M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $88.26M | $78.64M | $75.08M | $88.33M | $103.3M | $72.82M | $76.66M | $83.00M |
| Short-Term Investments | $201.3M | $255.9M | $276.8M | $289.6M | $229.3M | $192.7M | $227.2M | $316.0M |
| **Cash & Short-Term Investments** | $289.6M | $334.5M | $351.9M | $377.9M | $332.6M | $265.5M | $303.8M | $399.0M |
| **Total Current Assets** | $298.2M | $342.0M | $361.4M | $386.8M | $342.2M | $275.9M | $317.8M | $414.7M |
| Property, Plant & Equipment, Net | $210K | $263K | $342K | $421K | $489K | $569K | $607K | $683K |
| Long-Term Investments | $21.90M | $19.02M | $38.50M | $58.27M | $140.0M | $242.3M | $259.4M | $204.4M |
| Other Non-Current Assets | $297K | $297K | $297K | $297K | $361K | $367K | $366K | $366K |
| **Total Non-Current Assets** | $24.41M | $21.81M | $41.58M | $61.62M | $141.9M | $244.4M | $261.9M | $207.2M |
| **Total Assets** | $322.6M | $363.8M | $403.0M | $448.4M | $484.1M | $520.3M | $579.7M | $621.8M |
| Accounts Payable | $1.14M | $3.73M | $2.51M | $841K | $1.72M | $2.46M | $3.40M | $1.68M |
| Other Current Liabilities | $1.47M | $1.53M | $1.35M | $996K | $1.51M | $2.23M | $2.79M | $1.44M |
| **Total Current Liabilities** | $40.13M | $40.63M | $35.15M | $37.74M | $32.76M | $28.06M | $27.35M | $30.65M |
| **Total Non-Current Liabilities** | $1.15M | $1.41M | $1.66M | $1.90M | $0 | $125K | $493K | $849K |
| **Total Liabilities** | $41.27M | $42.03M | $36.81M | $39.64M | $32.76M | $28.18M | $27.84M | $31.50M |
| **Total Debt (incl. Leases)** | $2.00M | $2.07M | $2.38M | $2.68M | $1.19M | $1.52M | $1.84M | $2.15M |
| Common Stock | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained Earnings | -$740.9M | -$691.5M | -$637.8M | -$588.1M | -$537.4M | -$486.8M | -$416.7M | -$368.2M |
| Accumulated Other Comp. Income | -$652K | -$134K | $127K | $1.02M | $973K | $607K | $505K | -$133K |
| **Total Stockholders' Equity** | -- | -- | -- | $408.7M | $451.4M | $492.1M | $551.8M | $590.3M |
| Total Equity | $281.3M | $321.8M | $366.2M | $408.7M | $451.4M | $492.1M | $551.8M | $590.3M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$219.9M | -$167.6M | -$155.1M | $109.2M | -$67.48M | -$59.46M |
| Depreciation & Amortization | $311K | $306K | $310K | $93K | $53K | $62K |
| Stock-Based Compensation | $36.04M | $37.82M | $30.44M | $27.96M | $24.38M | $14.91M |
| Change in Payables | -$839K | -$812K | -$167K | -$509K | -$4.83M | $5.58M |
| **Operating Cash Flow** | -$175.8M | -$145.3M | -$134.3M | -$126.7M | -$43.43M | -$29.77M |
| Capital Expenditure | -$49K | $0 | -$208K | -$1.13M | $0 | -$10K |
| **Free Cash Flow** | -$175.8M | -$145.3M | -$134.5M | -$127.8M | -$43.43M | -$29.78M |
| Acquisitions, Net | -- | -- | -- | -- | -- | $1.45M |
| Purchases of Investments | -$236.5M | -$721.1M | -$373.4M | -$377.9M | -$525.8M | -$69.76M |
| **Investing Cash Flow** | $180.0M | -$136.3M | $35.81M | $249.0M | -$333.8M | -$5.42M |
| Common Stock Issued | $0 | $262.7M | $38.39M | $0 | $3.28M | $145.4M |
| Share Repurchases | -- | -- | -- | -- | -- | -$6.57M |
| **Financing Cash Flow** | $1.09M | $266.2M | $40.75M | -$25.93M | $268.8M | $140.1M |
| **Net Change in Cash** | $5.33M | -$15.43M | -$57.72M | $96.38M | -$108.4M | $104.9M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$49.39M | -$53.70M | -$49.66M | -$50.71M | -$50.61M | -$70.06M | -$48.50M | -$47.65M |
| Depreciation & Amortization | $53K | $79K | $79K | $79K | $79K | $77K | $76K | $77K |
| Stock-Based Compensation | $8.37M | $8.45M | $7.62M | $7.31M | $9.47M | $9.89M | $9.37M | $9.63M |
| Change in Payables | -$2.59M | $1.22M | $1.67M | -$879K | -$739K | -$941K | $1.72M | -$434K |
| **Operating Cash Flow** | -$43.08M | -$38.22M | -$46.05M | -$38.11M | -$36.88M | -$57.61M | -$43.16M | -$36.63M |
| Capital Expenditure | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Free Cash Flow** | -- | -- | -- | -- | -- | -- | -- | -$36.63M |
| Purchases of Investments | -$34.40M | -$14.57M | -$20.14M | -$19.60M | -$12.57M | -$78.53M | -$125.8M | -$168.0M |
| **Investing Cash Flow** | $51.64M | $40.68M | $32.41M | $22.39M | $67.39M | $53.40M | $36.80M | $15.96M |
| **Financing Cash Flow** | $1.06M | $1.10M | $380K | $715K | $0 | $373K | $0 | $1.58M |
| **Net Change in Cash** | $9.62M | $3.56M | -$13.25M | -$15.00M | $30.52M | -$3.83M | -$6.35M | -$19.08M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -- | -- | -358.7% | -- |
| **Net Profit Margin** | -- | -- | -- | -- | -346.1% | -- |
| Return on Equity (ROE) | -53.8% | -28.4% | -33.8% | 20.8% | -15.4% | -26.0% |
| Return on Assets (ROA) | -49.0% | -26.9% | -31.6% | 19.8% | -15.0% | -24.1% |
| Current Ratio | 10.25x | 13.53x | 17.07x | 21.09x | 25.25x | 14.82x |
| Quick Ratio | 10.01x | 13.02x | 16.60x | 20.77x | 24.73x | 14.68x |
| Debt to Equity | 0.01x | 0.00x | 0.01x | 0.01x | -- | -- |
| **Revenue Growth (YoY)** | -- | -- | -- | -100.0% | -- | -- |
| Operating Income Growth (YoY) | -- | -- | -232.1% | -- | -- | -- |
| **Net Income Growth (YoY)** | -- | -- | -237.7% | -- | -- | -- |
| EPS Growth (YoY) | -- | -- | -250.0% | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -- | -- | -53.8% | -48.0% | -42.0% | -32.4% | -28.4% |
| Return on Assets (ROA) | -63.1% | -56.3% | -54.9% | -49.0% | -44.8% | -39.7% | -30.8% | -26.9% |
| Current Ratio | 7.43x | 8.42x | 10.28x | 10.25x | 10.45x | 9.83x | 11.62x | 13.53x |
| Quick Ratio | 7.22x | 8.23x | 10.01x | 10.01x | 10.15x | 9.46x | 11.11x | 13.02x |
| Debt to Equity | -- | -- | -- | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
